The unscientific criticism of AstraZeneca could do lasting damage

Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.

The AstraZeneca vaccine has suffered a setback in the past few days as France, Germany and Italy have joined a “growing list” of European countries, now more than a dozen in total, to halt its use “temporarily”, says The Economist. A few countries in the rest of the world, including Indonesia, have followed suit. This “wave of suspensions” has been set in motion by data from a Norwegian medical regulator reporting four cases of blood clotting in adults given the vaccine. Similar scattered reports of blood clots “have come from Denmark, Italy and Austria”.

Those countries suspending the vaccine are behaving irrationally, says David Spiegelhalter in The Guardian. While suspected reactions “should be investigated”, moving too fast may lead to regulators “drawing causal links between events where none may exist”. 

Given that one in 5,000 people end up having a blood clot each year, it is “not at all surprising” that there have been 30 reports of blood clots so far from the five million people who have had AstraZeneca’s vaccine, especially since most vaccinations have occurred among the elderly and infirm. This hardly means the vaccine caused the clots. If anything, all the data so far has demonstrated how “extraordinarily safe” both the AstraZeneca and the Pfizer vaccines are.

Lasting reputational damage

Experts agree that the decisions to suspend the vaccine look wrong, especially since the European Medicines Agency (EMA), the EU’s main regulator, continues to defend it, says Paul Cullen in the Irish Times. However, even if these countries eventually change their minds, the damage to the reputation of the AstraZeneca vaccine will be “massive and possibly lasting”. Despite its “impressively high effectiveness in real-world trials”, disparaging comments by many European politicians, as well as a perception that it is less effective in older patients, mean that it is facing a high degree of “consumer resistance”.

Concern over blood clots and lower effectiveness aren’t the only problem that AstraZeneca is up against, say Suzi Ring and Michelle Fay Cortez on Bloomberg. There is also the ongoing controversy over “manufacturing issues”, which means that the company will “only be able to deliver about 100 million doses to the EU in the first half of the year”, about one-third of the number originally planned.

AstraZeneca’s loss could be other companies’ gain, says Aimee Donnellan on Breakingviews. The EU has set itself a target of vaccinating 70% of its population, around 350 million people, by the summer. But without AstraZeneca’s vaccines, it will only have enough for 250 million people. So if Europe is to avoid having to impose more lockdowns in the winter, when infections start to pick up, Brussels will need to “speedily approve and distribute” other candidates, such as Johnson & Johnson’s jab, which got the nod from the EMA last week. 

Recommended

Will the government’s green plans hit the price of your home?
House prices

Will the government’s green plans hit the price of your home?

UK house prices are still rising fast. But the government’s plan to reach net-zero carbon emissions could halt that – for some of us, at least. John S…
21 Oct 2021
If you want to get exposure to bitcoin, I have this great idea for you
Bitcoin & crypto

If you want to get exposure to bitcoin, I have this great idea for you

As bitcoin climbs to new highs, you can now buy a bitcoin ETF. But if you really want to get some exposure to bitcoin, there’s a much better way, says…
20 Oct 2021
Too embarrassed to ask: what is a dividend yield?
Too embarrassed to ask

Too embarrassed to ask: what is a dividend yield?

Learn what a dividend yield is and what it can tell investors about a company in MoneyWeek's latest “too embarrassed to ask” video.
19 Oct 2021
Index tracker funds won't shield your wealth from inflation – here's why
Investment strategy

Index tracker funds won't shield your wealth from inflation – here's why

If you want your portfolio to survive in an inflationary world, a broad index-tracker fund won’t cut it. You need to be a lot more selective than that…
19 Oct 2021

Most Popular

How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
How to invest in SMRs – the future of green energy
Energy

How to invest in SMRs – the future of green energy

The UK’s electricity supply needs to be more robust for days when the wind doesn’t blow. We need nuclear power, says Dominic Frisby. And the future of…
6 Oct 2021
Why the world’s most important economic data release has unnerved markets
US Economy

Why the world’s most important economic data release has unnerved markets

The US added only 194,000 jobs in September, far shorter than the 500,000 that were expected. John Stepek explains why markets didn't react as they no…
11 Oct 2021